Loading...
MTAA
PHN
Market cap984mUSD
Jul 09, Last price  
89.30EUR
1D
-0.89%
1Q
13.18%
IPO
544.77%
Name

Pharmanutra SpA

Chart & Performance

D1W1MN
MTAA:PHN chart
P/E
43.05
P/S
6.54
EPS
2.07
Div Yield, %
1.12%
Shrs. gr., 5y
-0.23%
Rev. gr., 5y
17.63%
Revenues
132m
+13.38%
26,254,66432,998,46937,784,56446,672,50353,811,00058,480,00068,144,00083,394,000101,034,000116,148,000131,687,000
Net income
20m
+20.43%
2,571,9333,850,8386,030,4898,557,4978,454,00014,072,00013,771,00015,048,00012,832,00016,609,00020,002,000
CFO
20m
-4.58%
05,861,3865,706,2876,436,10011,983,00011,791,00020,413,00014,466,00012,092,00020,501,00019,562,000
Dividend
May 05, 20251 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise, focusing on the research, development, design, and marketing of nutritional supplements and medical devices. Its market reach extends across Italy, other parts of Europe, the Middle East, the Far East, and globally. Moreover, the company manufactures and promotes pharmaceuticals, medical devices, over-the-counter (OTC) items, and nutraceuticals specifically for the pediatric population. Furthermore, Pharmanutra is a producer and supplier of raw materials and active ingredients to the food, pharmaceutical, and dietary supplement industries. Its diverse product portfolio features prominent brands like the SiderAL series (including SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med), the Cetilar range (Cetilar Crema, Cetilar Patch, Tape), along with ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. These products are distributed and sold through a network comprising sales representatives, wholesalers, pharmacies, and para-pharmacies. Established in 2003, the company's base of operations is in Pisa, Italy.
IPO date
Jul 18, 2017
Employees
Domiciled in
IT
Incorporated in
IT

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT